Calico (company)
 |
|
| Subsidiary | |
| Industry | |
| Founded | September 18, 2013 |
| Founders | |
| Headquarters | 1170 Veterans Blvd, South San Francisco, California, United States |
|
Area served
|
Worldwide |
|
Key people
|
Arthur D. Levinson (CEO) |
| Parent |
Google (2013–2015) Alphabet Inc. (2015–present) |
| Website | calicolabs |
Calico is an independent research and development biotech company founded on September 18, 2013 by Google and Arthur D. Levinson with the goal of combating aging and associated diseases. In Google's 2013 Founders' Letter, Larry Page described Calico as a company focused on "health, well-being, and longevity." The company's name is an acronym for "California Life Company".
In August 2015, Google announced plans to restructure into Alphabet Inc., wherein Google and Calico would become two of the subsidiaries of the new company along with others. This was completed on October 2.
In September 2014, it was announced that Calico, in partnership with AbbVie, would be opening up a R&D facility focused on aging and age-related diseases, such as neurodegeneration and cancer. Initially, each company will invest $350 million, with an option for each to add an extra $500 million later on. In the same month, Calico announced a partnership with the University of Texas Southwestern Medical Center and 2M Companies regarding drug development for neurodegenerative disorders.
In 2015, the Broad Institute of MIT and Harvard announced a partnership with Calico to "advance research on age-related diseases and therapeutics", a further partnership also was announced with the Buck Institute for Research on Aging. Also in 2015, Calico announced a partnership with QB3 based on researching the biology of aging and identifying potential therapeutics for age-related diseases and one with AncestryDNA based on conducting research into the genetics of human lifespan.
Calico has licensed experimental drug compounds P7C3 analogues involved in enhancing the activity of the enzyme nicotinamide phosphoribosyltransferase, which plays a role in nicotinamide adenine dinucleotide biosynthesis. P7C3 compounds have previously been shown in a number of publications to be beneficial in animal models for age-related neurodegeneration. The partnership involves upfront and milestone payments for development of the compounds into therapeutics.
...
Wikipedia